alzAPOE therapeutics change feed
Snapshot

APOE genotype selects responders and governs risk; the therapeutic itself targets something else

4 tracked therapeutics, 19 registered studies.

1 source is not reporting cleanly — changes may be missingeuropepmc STALE

Changes that would have come from the sources below are absent from this feed. Absence here means “not observed”, not “did not happen”.

  • Europe PMC (europepmc, daily) — last successful fetch (2 days ago), last run status ok — past its staleness threshold.

Maturity

  1. ObservationA phenomenon has been noted.
  2. Target validationA causal role has been tested in models.
  3. Tool compoundA molecule engages the target but is not developable.
  4. Development candidateA specific therapeutic is in preclinical development.
  5. ClinicalAt least one therapeutic is in human trials.

Clinical — At least one therapeutic is in human trials. This value is set by a curator and is not derived from the therapeutics below: a thesis with no therapeutics still has a maturity, and that is the case this entity exists to express. The furthest any therapeutic here has reached is approved.

Therapeutics pursuing this thesis — 4

TherapeuticSponsorModalityStatusTrialsPubsLast change
AGB101AgeneBiosmall moleculePhase 240none observed
ALZ-801 (valiltramiprosate)Alzheonsmall moleculePhase 350none observed
donanemabEli LillyantibodyApproved60· 2 days ago
lecanemabEisai / BiogenantibodyApproved40· 2 days ago

Evidence — 0

No publication is linked to this thesis yet. Papers attach to a thesis only when a human approves the link — the same rule that governs therapeutic-level citations. An unlinked literature is an unworked queue, not an absent one.

Change history across this thesis — 3

Last reviewed by a curator (yesterday). A thesis nobody has re-examined is an opinion presented as a position.